Capivasertib, buparlisib, and taselisib share the capability of acting along the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of the rapamycin (mTOR) signaling pathway, which is often over-expressed in breast cancer [89], determining an increase in cellular motility and proliferation and a reduced effect of cytotoxic agents [90]. This evidence concerns the gene MTOR and breast carcinoma.